Idiopathic Pulmonary Fibrosis

August 26, 2016August 26, 2016

Vanderbilt’s IPF Researchers Awarded $11M Grant to Study Genetics of Disease

The National Heart, Lung and Blood Institute (NHLBI) has awarded Vanderbilt University Medical Center (VUMC) an $11 million project renewal grant to study the genetics and biological mechanisms behind idiopathic pulmonary ... Read more

August 17, 2016August 17, 2016

Pulmonary Problems Can Plague Childhood Cancer Survivors Through Adult Life

Asthma, Emphysema, Idiopathic Pulmonary Fibrosis, News, Pneumonia

Pulmonary complications can mount in childhood survivors of cancer for as long as 25 years after initial diagnosis, and have a substantial impact on their daily life, a team of researchers ... Read more

August 8, 2016August 8, 2016

Early Treatment with Esbriet Can Help Slow IPF Progression, Study Finds

Idiopathic Pulmonary Fibrosis, News

Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease, and patients have very few options once the disease seriously progresses. Now, a study from the University of Turin, Italy, suggests ... Read more

August 2, 2016August 2, 2016

Trial Launches to Evaluate Ofev on IPF-Predicting Biomarkers

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals announced the launch of a new clinical trial to investigate the effects of Ofev (nintedanib) on certain blood biomarkers that might help identify fibrosis and loss of lung function ... Read more

July 29, 2016July 29, 2016

US DOD Grants $11.5M to Study Lung Diseases in Middle East War Vets

Idiopathic Pulmonary Fibrosis, News

Thanks to $11.5 million in grants from the U.S. Department of Defense, researchers from the National Jewish Health respiratory treatment center in Denver will study why veterans who were deployed to the Middle ... Read more

July 27, 2016July 27, 2016

AdAlta Goes Public to Speed New Therapies for Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

AdAlta, a drug company, is looking to raise $10 million with an initial public offering (IPO) on the Australian Securities Exchange. The sum will be used to support trials on AD-114, the company’s lead ... Read more

July 18, 2016July 18, 2016

Windtree Given Third $1 Million Grant to Develop Way of Treating Lung Injury Due to Radiation

Idiopathic Pulmonary Fibrosis, News

Windtree Therapeutics recently announced that it has received the third $1 million installment in a previously announced Phase 3 Small Business Innovation Research (SBIR) grant, worth about $3 million in total, to support development ... Read more

July 14, 2016July 14, 2016

ProterixBio Appoints Pulmonary Disease Expert to Scientific Advisory Board

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

ProterixBio (formerly BioScale) appointed Dr. Fernando Martinez, MD, to its scientific and medical advisory board. The Massachusetts-based company says the addition of Martinez, a global clinical expert in pulmonary diseases such ... Read more

June 30, 2016June 30, 2016

Lung Disease, New Inhaled Treatments by Pulmatrix Described in Animated Science Video

Asthma, COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

A life sciences animated video was recently released by Pulmatrix to explain breathing issues experienced by patients with serious lung diseases and to illustrate novel promising therapies developed by the company. The ... Read more

June 28, 2016June 28, 2016

Analysis Shows IPF Treatment OFEV (Nintedanib) Effective in Test, Broader Criteria

Idiopathic Pulmonary Fibrosis, News

The latest analysis of Inpulsis clinical trials demonstrated that Ofev (nintedanib) for idiopathic pulmonary fibrosis slows the disease progression and that treatment results are similar using broader diagnostic criteria than required. The data was ... Read more